Firtecan pegol

Drug Profile

Firtecan pegol

Alternative Names: BEL-0222; EZN-2208; PEG-SN38; Pegylated-SN-38; SN38-PEG

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Enzon Pharmaceuticals
  • Developer Belrose Pharma; Enzon Pharmaceuticals; National Cancer Institute (USA)
  • Class Antineoplastics; Camptothecins; Polyethylene glycols
  • Mechanism of Action Angiogenesis inhibitors; DNA topoisomerase I inhibitors; Hypoxia-inducible factor-1 alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer
  • Phase I/II Neuroblastoma; Solid tumours
  • Discontinued Colorectal cancer; Lymphoma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Metastatic disease) in USA (IV, Infusion)
  • 14 Jun 2016 Biomarkers information updated
  • 15 Jul 2013 Phase-I clinical trials in Solid tumours (combination therapy, metastatic disease) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top